Praxis Precision Medicines Partners to Enhance Genetic Testing Access for Pediatric Epilepsy

Improving Access to Genetic Testing for Pediatric Epilepsy

GeneDx, a leader in genomic insights, has launched a significant Patient Access Program aimed at addressing the diagnostic challenges faced by children with epilepsy. Collaborating with Biogen, Praxis Precision Medicines, and Stoke Therapeutics, this initiative responds to the extensive 5–8-year journey many families endure in pursuit of a definitive genetic diagnosis. With over 700 genes linked to seizure disorders, the limitations of traditional commercial gene panels—often covering less than 50% of these genes—underscore the necessity for whole exome sequencing. The program's core objective is to enhance access to this advanced genetic testing, which has demonstrated a capability to provide a genetic diagnosis for nearly 25% of seizure patients, surpassing the traditional 19% yield from standard gene panels.

The endorsement of whole exome sequencing as a first-line approach for unexplained epilepsy by both the National Society of Genetic Counselors and the American Epilepsy Society emphasizes the importance of this testing method. However, despite its advantages, disparities in access continue to obstruct equitable care, leaving many patients without timely diagnoses. GeneDx's initiative seeks to bridge these gaps, aiming to make whole exome sequencing more widely available to affected families. By doing so, the program not only addresses immediate needs but also enriches GeneDx’s extensive database of over 700,000 exome and genome results, which in turn supports ongoing research into the genetic underpinnings of seizure-related conditions.

Melanie Duquette, Chief Growth Officer of GeneDx, highlights the urgency of understanding the genetic origins of epilepsy, a condition that impacts nearly half a million children under 18 in the United States. By facilitating improved access to genetic testing, the Patient Access Program aspires to provide crucial answers for families while paving the way for the development of personalized treatments and therapies in the future. This initiative exemplifies a broader commitment to advancing research and development within the biopharma sector, showcasing the potential of genetic insights to transform the landscape of care for children with epilepsy.

In related news, Praxis Precision Medicines continues to focus on innovative treatments for neurological disorders, positioning itself as a key player in the evolving landscape of precision medicine. The collaboration with GeneDx in this patient access initiative highlights the company's commitment to addressing unmet medical needs through genetic research and enhanced diagnostic capabilities. As the industry moves towards more personalized healthcare solutions, such partnerships will play a crucial role in reshaping patient outcomes in neurology.